7 Mar 2019 07:00
Silence Therapeutics to Present at the 2019 Cowen Health Care Conference
March 07, 2019
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces that Dr. David Horn Solomon, Chief Executive Officer of Silence Therapeutics, is scheduled to present an overview and Company update as well as host investor meetings at the 39th Annual Cowen Health Care Conference.
Details of the Silence Therapeutics company presentations and webcasts are as follows:
Event: | 39th Annual Cowen Health Care Conference | |
Date: | Monday, March 11, 2019 | |
Time: | 1:30 p.m. EDT (5:30 p.m. GMT) | |
Location: | The Boston Marriott Copley Place, Boston, Mass. |
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
A live webcast of the presentation can be accessed by visiting 'Results, reports & presentations' in the Investors Section on the Company's website at www.silence-therapeutics.com. An archived replay of the webcast will be available for 60 days on the Company's website after the conference.
Enquiries:
Silence Therapeutics plc Dr David Horn Solomon, Chief Executive Officer Rob Quinn, Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
European IR Consilium Strategic Communications Mary-Jane Elliott/Angela Gray silencetherapeutics@consilium-comms.com
| Tel: +44 (0) 20 3709 5700 |
US IR Westwicke Partners Peter Vozzo Peter.vozzo@westwicke.com | Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and
delivery systems are designed to improve the stability of our molecules and enhance effective delivery
to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
For more information, please visit: https://www.silence-therapeutics.com/
SLN.L (SLN)